BTMD vs USNA
biote Corp. and Usana Health Sciences Inc., side by side — 5 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BTMD | USNA |
|---|---|---|
| Revenue | $192.2M | $925.3M |
| Net income | $27.0M | $10.8M |
| Gross margin | 71.5% | 78.3% |
| Net margin | 16.4% | 1.2% |
| Return on equity | — | 2.0% |
| Diluted EPS | $0.74 | $0.58 |
| Dividend / share | — | — |
| Payout ratio | 6.4% | — |
| Free cash flow | $30.2M | $8.5M |
| Equity | $-58.5M | $533.1M |
| Net debt / equity | — | — |
| Current ratio | 1.22× | 2.24× |
| Revenue CAGR 5y | — | −4.0% |
| Profit CAGR 5y | — | −38.7% |
USNA bills 4.8× the revenue of BTMD, and BTMD keeps more of each dollar of revenue as profit (16.4% against 1.2%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
5 years side by side
| Fiscal year | BTMD | USNA |
|---|---|---|
| FY2025 | $192.2M | $925.3M |
| FY2024 | $197.2M | $854.5M |
| FY2023 | $185.4M | $921.0M |
| FY2022 | $165.0M | $998.6M |
| FY2021 | $139.4M | $1.2B |
Net income by year
Bottom line
| Fiscal year | BTMD | USNA |
|---|---|---|
| FY2025 | $27.0M | $10.8M |
| FY2024 | $3.2M | $42.0M |
| FY2023 | $3.3M | $63.8M |
| FY2022 | $-969,000 | $69.3M |
| FY2021 | $32.6M | $116.5M |
More in this industry